Could qelbree tame ADHD and mood swings in adults?

NCT ID NCT06185985

Completed Disease control Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug Qelbree (viloxazine) in 161 adults with ADHD who also had mood symptoms. Participants took the medication for several weeks, and researchers tracked changes in ADHD symptoms using a standard rating scale. The goal was to see if Qelbree is both safe and effective for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Qelbree (viloxazine extended-release capsules)
What this could lead to: If successful, this could show that Qelbree is a safe and effective option for adults with ADHD who also have mood symptoms, potentially expanding treatment choices.
What could go wrong: This was an open-label trial with no placebo group, so results may be less reliable. The study is completed but not yet published, so we don't know the outcomes. Side effects are possible, as with any medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT HYPERACTIVITY DISORDER

Contacts and locations

Locations

ObvioHealth

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.